Verona Pharma (VRNA)
(Real Time Quote from BATS)
$15.14 USD
-0.30 (-1.94%)
Updated Jun 28, 2024 10:42 AM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Verona Pharma PLC American Depositary Share [VRNA]
Reports for Purchase
Showing records 121 - 140 ( 192 total )
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Financing Clears Key Overhang; All Set to Start Ensifentrine Ph 3 in H2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine/COPD ENHANCES to Phase 3; KOLs Enthusiastic
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
FDA?s EOP2 Response Supports Ph3 ENHANCE Program Initiation
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q1; Ensifentrine/COPD: FDA?s EOP2 Response Anticipated in Q2; Ph3 Start in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
2020 Updated Outlook; Verona Can Manage Nebulized Ph 3 but Financing Required
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Positive Data for Ph2 pMDI Single Dose; Multiple Dose Postponed Due to COVID-19
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q4/FY19; Ensifentrine/COPD: End-of-Ph2 Meeting in Q2; Potential Ph3 Start in Q3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine/COPD: Ph2b Data Published; Next-Topline Ph2 pMDI Results in Q1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L